Syed A Hussain
@ProfSyedHussain
Followers
753
Following
2K
Media
72
Statuses
634
Professor of Medical Oncology Department of Oncology and Metabolism Medical School, Beech Hill Road, Sheffield
University of Sheffield
Joined August 2016
Great study and result in this neglected patient population and an area of unmet need. Time to turn the corner for this subset of patients with large randomised trials through international GU collaborations. @DrYukselUrun @PGrivasMDPhD @arkhaki @RubenRaychaud @spsutkaMD.
Congrats to all who made this possible. This trial showed 53% pCR and 64% 2‑yr EFS with neoadjuvant chemo‑immunotherapy in non-urothelial MIBC subtypes. Time for collaboration and more studies in this neglected population. @RubenRaychaud @arkhaki @spsutkaMD @PGrivasMDPhD
0
5
9
ESMO Advanced Course on ADC Development, Therapeutic Applications and Research in Genitourinary Cancers 2025: Zurich | ESMO Gr8 opportunity for ESMO members to join us during this exciting educational meeting. @myESMO @giannatempopatr
0
3
5
These are exciting results providing an excellent option for these patients. Management of BCG unresponsive high risk NMIBC continues to evolve!.
TAR-200 for BCG-unresponsive high-risk NMIBC. 🟡CR: 82%, DOR: 26 months (TAR-200 alone).🟡Best risk-benefit: TAR-200 monotherapy—better than combo or PD-1 alone. @ASCO @JCO_ASCO @OncoAlert @WorldBladderCan @siadaneshmand @AndreaNecchi @MichvdHeijden @DrFelixGuerrero @y_loriot
0
1
3
Great to see the international collaborations moving the field forward and answering questions within randomised trials to further improve clinical outcome & QOL gains for our patients globally. @KariTikkinen @DrYukselUrun @JimCatto @drenriquegrande @ASCO @sheffielduni @cdanicas.
@DrYukselUrun @AnkaraUni @Uroweb @akpinarcagri @ProfSyedHussain @MariaJRibal @JimCatto @drenriquegrande @GGiannarini @Albert0Briganti @amerseburger @yekeduz_emre @itinay @medicalwatchBC Thank you so much @DrYukselUrun @AnkaraUni for the kind words and warm welcome! Great to exchange ideas and explore future collaborations! Looking forward to what we can achieve together. @Uroweb @helsinkiuni @ProfSyedHussain @JimCatto.
1
1
13
RT @DrYukselUrun: Thank you for visiting us @KariTikkinen .Great minds, great energy, more than happy to collaborate. Let’s build new ideas….
0
7
0
RT @DrYukselUrun: @US_FDA approves durvalumab for perioperative immunotherapy for patients with muscle-invasive bladder cancer.In a prespe….
0
7
0
RT @OncoAlert: Day TWO #GUARDSymposium2025 🚨.Presentation by @ProfSyedHussain . One line, several options: individualization of treatment….
0
12
0
RT @DrYukselUrun: Durvalumab approved in the 🇪🇺EU as the first and only perioperative immunotherapy for muscle-invasive bladder cancer. Bas….
0
15
0
RT @FaltasLab: 🚀Big News! Excited to share our work “The Interplay of Mutagenesis and ecDNA Shapes Urothelial Cancer Evolution” published i….
0
64
0
RT @OncoAlert: LIVE Day TWO #GUARDSymposium2025 Presentation by Dr. Matt Galsky🇺🇸 How to select patients in whom we preserve the bladder wi….
0
20
0
It was my pleasure to contribute and present at the exciting GUARD symposium. Delighted 2 see its growth &new research developed under its wings. @tompowles1 @MattGalsky @AndreaNecchi .@DrIacovelli @JimCatto @cdanicas .@drenriquegrande @DrFelixGuerrero @CParkMD @DrYukselUrun
🌟🟠 Powerful insights by @ProfSyedHussain at @GuardConsortium #GUARDSymposium2025 @OncoAlert.💡 One disease, many paths in mUCl.🔹 >50% of mUC patients receive no 1L treatment.🔹 High dropout rate despite multiple available options.🔹 Key decision drivers: efficacy,
3
7
20
RT @nataliagandur: 🌟🔵 Perioperative IO in MIBC: where are we heading?.Presentation by Dr. @AndreaNecchi #GUARDSymposium2025.@OncoAlert @AP….
0
10
0
RT @nataliagandur: 🌟🟠 Bladder Sparing in MIBC.Presented by @MattGalsky @MountSinaiCancer.@OncoAlert @GUARDConsortium #GUARDSymposium2025.👀….
0
10
0
RT @OncoAlert: A GREAT DAY TWO of #GUARDSymposium2025 JOIN US TODAY FOR THIS FINAL DAY.REGISTER👉 STILL NOT TOO LAT….
0
12
0
RT @nataliagandur: 🌟🔵 Rethinking high-risk NMIBC: from BCG to future paradigms.@DrFelixGuerrero @OncoAlert #GUARDSymposium2025.A powerful s….
0
14
0
RT @nataliagandur: 🌟🔵 Redefining metastatic hormone-sensitive prostate cancer.@docjavip @OncoAlert #GUARDSymposium2025. 🔹 Timing & burden d….
0
15
0
RT @DrYukselUrun: 🧬In MIBC, deleterious DDR gene alterations, especially ERCC2, show promise as markers for better response to cisplatin-ba….
0
16
0
RT @OncoAlert: Day One 🚨 #GUARDSymposium2025.AI in diagnostic imaging being presented by Dr. Almudena Fuster. AI is revolutionizing genito….
0
11
0
RT @OncoAlert: Join us for the GUARD Symposium🇪🇸 featuring interactive workshops where experts collaboratively discuss real-world genitouri….
0
8
0